Company Filing History:
Years Active: 2016
Title: Hirofumi Toi: Innovator in Anti-Endoglin Antibodies
Introduction
Hirofumi Toi is a prominent inventor based in Hokkaido, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of therapies targeting angiogenesis-associated diseases. His innovative work has led to the creation of valuable patents that advance medical science.
Latest Patents
Hirofumi Toi holds a patent for "Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin." This patent provides compositions and methods related to the prophylaxis and therapy of diseases associated with angiogenesis. It includes novel knockin mice that express a human/mouse chimeric endoglin, vectors for creating such mice, and murine embryonic stem cells containing the novel human/mouse transgene. Additionally, the patent features anti-human endoglin monoclonal antibodies (mAbs) that can serve as antiangiogenic agents for the prevention or treatment of human tumor angiogenesis and diseases characterized by excessive vascularization. Importantly, these mAbs do not cross-react with murine endoglin, ensuring specificity in their application.
Career Highlights
Hirofumi Toi has established himself as a key figure in the field of health research. He is associated with Health Research, Inc., where he continues to explore innovative solutions to complex medical challenges. His work has garnered attention for its potential impact on treating various angiogenesis-related conditions.
Collaborations
Hirofumi Toi collaborates with notable professionals in his field, including Ben K Seon. These partnerships enhance the research and development of new therapeutic approaches, contributing to advancements in medical science.
Conclusion
Hirofumi Toi's contributions to the field of biomedical research, particularly through his patent on anti-endoglin antibodies, highlight his role as an innovator. His work not only advances scientific understanding but also holds promise for improving therapeutic strategies against angiogenesis-associated diseases.